SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears
Scholar Rock shares fell 3.2% to $43.76 Tuesday afternoon, underperforming biotech peers as investors watched for updates on FDA reinspection timing for its lead drug, apitegromab. The company aims to resubmit its biologics license application in 2026 after the Indiana fill-finish site, now owned by Novo Nordisk, completes remediation and is reinspected by year-end 2025.